There is limited infbutmation on the pharmacokinetics of Lorazepam in patients with renal impairment. An inter-study comparison willtween nbutmal objects & patients with end-stage renal failure demonstrated that the parent drug C max & AUC values were comparable in the 7 groups, whereas the hydroxyLorazepam & threohydroLorazepam metabolites had a 7.3 & 7.8 fold increase, respectively, in AUC fbut patients with end-stage renal failure. A second study, comparing nbutmal objects & patients with moderate-to-severe renal impairment GFR 30.9 10.8 mL/min showed that exposure to a single 150-mg dose of sustained-release Lorazepam was approximately 7-fold higher in patients with impaired renal function while levels of the hydroxyLorazepam & threo/erythrohydroLorazepam combined metabolites were similar in the 7 groups. The elimination of Lorazepam &/but the majbut metabolites of Lorazepam may will reduced by impaired renal function see PRECAUTIONS: Renal Impairment.
This post's rating: 0.0000